Clinical Trials Browser

Carcinoma, Hepatocellular

NCT04889066 2024-12-20

Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05718297 2024-10-08

BOUNCE

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05757843 2024-09-19

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04944173 2024-09-03

SCION

Phase 2 Withdrawn

Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm, Residual

NCT05572476 2024-06-05

LURBIMUNE

Phase 2 Withdrawn

Thoracic

Small Cell Lung Carcinoma

NCT05209529 2024-02-23

Chemo-free BRCA-targeted Neoadjuvant Strategy

Phase 2 Withdrawn

Breast

Triple Negative Breast Neoplasms

NCT05161533 2023-10-18

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

Phase 2 Withdrawn

Thoracic

Lung Neoplasms

NCT03982173 2023-01-26

MATILDA

Phase 2 Withdrawn

BreastGastrointestinal

Adenocarcinoma Of Esophagus, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT05383001 2022-09-27

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04001413 2022-07-29

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

Phase 2 Withdrawn

Head & Neck

Oropharyngeal Neoplasms

NCT03319316 2022-01-10

SOLUTION

Phase 2 Withdrawn

Thoracic

Squamous Non-small Cell Lung Cancer

NCT04262375 2020-11-17

DOMINATION

Phase 2 Withdrawn

GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell

NCT04262388 2020-11-17

DOME

Phase 2 Withdrawn

Head & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung

NCT04184518 2020-06-02

CEDUVEAL-M

Phase 2 Withdrawn

Dermatologic

Uveal Melanoma, Neoplasm Metastasis

NCT02885727 2019-09-12

Panc-Durval+RT

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT03419559 2019-04-16

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03241017 2018-04-09

IDA-D

Phase 2 Withdrawn

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT03004105 2018-03-16

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02966587 2018-01-17

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 2 Withdrawn

Microsatellite Instability

NCT02673814 2016-08-01

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer

Phase 2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung

Clinical Trials

PRISM

Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases

BOUNCE

Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab

SCION

LURBIMUNE

Chemo-free BRCA-targeted Neoadjuvant Strategy

Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial

MATILDA

Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy (Re-Check)

Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients

SOLUTION

DOMINATION

DOME

CEDUVEAL-M

Panc-Durval+RT

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

IDA-D

MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)

Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer